Long‐term safety results from a phase 3 open‐label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate‐to‐severe plaque psoriasis
暂无分享,去创建一个
M. Lebwohl | D. Pariser | R. Israel | L. Gold | J. Sugarman | R. Pillai | S. Harris | T. Lin | Gina Martin